Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vyant Bio, Inc. (CGIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/16/2022 8-K Quarterly results
09/15/2020 8-K Investor presentation
08/14/2018 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates",
"— Slide presentation for Q2 2018 earnings call"
05/15/2018 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates"
04/02/2018 8-K Investor presentation, Quarterly results
Docs: "—",
"—"
11/09/2017 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies",
"Q3 2017 Earnings Report & Company Updates Thursday - November 9, 2017 08:30am Eastern CEO: Panna Sharma webcast link: http://public.viavid.com/player/index.php?id=127177 Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact should also be considered to be forward-looking ..."
08/14/2017 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics, Inc. Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise",
"Cancer Genetics Announces Transformative and Accretive Acquisition of vivoPharm, a Global Oncology & Immuno-Oncology Discovery Services Company ▪ Acquisition Strengthens CGI’s Bench-to-Bedside Capabilities and Bolsters Growth with Global Customer Base of Biopharma Partners ▪ Expands Discovery and Early Development Revenue Base with Highly Complementary Biotechnology and Pharmaceutical Customers, Especially in Europe and Asia-Pacific ▪ Acquisition is Expected to be Immediately Accretive Based on vivoPharm’s History of Profitability ▪ Increases Immuno-Oncology and Pharmacology Capabilities Adding Over 55 New Projects with Over 30 in Immuno-Oncology ▪ Transforms Operations & Value Proposition by Increasing Drug Identification, Drug Rescue and Drug Repurposing Cap...",
"– Slide presentation for Q2 2017 earnings call"
05/11/2017 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics, Inc. Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability ▪ Revenue increased to $7.0 million in Q1 2017, up 15% compared to Q1 2016 on strong organic growth ▪ Test volumes increased 19% year-over-year to 12,310 ▪ Gross profit margin was 40%, up from 32% for Q1 2016 ▪ Reduced total operating expenses 21% to $5.6 million in Q1 2017, down from $7.1 million in Q1 2016 ▪ Reduced first quarter loss from operations by 46% compared to Q1 2016, improving pathway to profitability ▪ Strengthened balance sheet with exercise of warrants, adding $1.8 million in cash ▪ Conference call begins at 9:00 a.m. Eastern, Friday, May 12, 2017",
"– Slide presentation for Q1 2017 earnings call"
03/23/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
05/10/2016 8-K Form 8-K - Current report
03/10/2016 8-K Form 8-K - Current report
11/10/2015 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics, Inc. Announces Strong Third Quarter and Year-to Date 2015 Results",
"– Slide presentation for Q3 2015 earnings call"
08/11/2015 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Announces Strong Second Quarter 2015 Results",
"– Slide presentation for Q2 2015 earnings call",
"Press release",
"– Slide presentation of investor frequently asked questions"
05/12/2015 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Announces Strong First Quarter 2015 Results • Company Reports Record Quarterly Revenues of $4.4 million, an Increase of 206% vs. First Quarter 2014 • Next-Generation Sequencing Panels Rapidly Progress into Usage by Both Clinical and Biopharma Customers • Cancer Genetics to Host Conference Call Today, Tuesday, May 12th, at 8:30am Eastern Time /5:30am Pacific",
"– Corporate presentation"
03/12/2015 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Announces Record Fourth Quarter and Full-Year 2014 Revenue • Fourth Quarter Revenues up 118 Percent Year over Year to $4 million • Full-Year 2014 Revenue Increase up 54 Percent over 2013 to $10.2 Million • Cancer Genetics to Host Conference Call Today, Thursday March 12th at 8:30 am Eastern Time / 5:30 am Pacific Time",
"– Corporate Presentation"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy